Live In Play®
Updated: 31-May-24 08:06 ET
AUTL:  Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO   (3.99)
  • The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes
  • 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention
  • Ongoing CAR T persistence was associated with improved event-free survival
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.
Send
Chat Icon